Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial

BackgroundRecently, the combination of immunotherapy with chemotherapy has been recommended as first-line treatment of metastatic gastric/gastroesophageal junction (G/GEJ) in the clinical guidelines of many countries; the therapeutic potential of this application needs to be further investigated for...

Full description

Bibliographic Details
Main Authors: Yuping Yin, Yao Lin, Ming Yang, Jianbo Lv, Jiaying Liu, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Jianfeng Shen, Peng Zhang, Kaixiong Tao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
tislelizumab
PD-L1 inhibitor
combination therapy
neoadjuvant therapy
gastric cancer
machine learning algorithm
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.959295/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.959295/full

Similar Items